Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;44(11):2431-2434.
doi: 10.1007/s00296-024-05571-y. Epub 2024 Mar 20.

Secukinumab is not associated with cancer recurrence or progression in patients with spondyloarthritis and history of neoplastic disease

Nicola Farina  1 , Alessandro Tomelleri  2   3 , Nicola Boffini  2 , Adriana Cariddi  2 , Stefania Calvisi  2 , Elena Baldissera  2 , Marco Matucci-Cerinic  2   3 , Lorenzo Dagna  2   3
Affiliations

Secukinumab is not associated with cancer recurrence or progression in patients with spondyloarthritis and history of neoplastic disease

Nicola Farina et al. Rheumatol Int. 2024 Nov.

Abstract

Secukinumab is a monoclonal antibody directed against interleukin-17 approved for the treatment of psoriasis and spondyloarthritis. The favorable oncological profile of secukinumab in patients with a history of malignancy has been shown in patients with psoriasis. However, systematic data to this regard have not been published yet for patients with spondyloarthritis. The objective of the present study was to evaluate the oncological safety of secukinumab in patients affected by this group of diseases. We performed a retrospective study in which we identified from our cohort patients with spondyloarthritis treated with secukinumab and with a history of malignancy. These patients' baseline demographic, treatment, rheumatological, and oncological data were collected. The neoplastic outcome (i.e., cancer recurrence or progression) after secukinumab start was then analyzed. Our study included 22 patients with spondyloarthritis. The most frequently reported oncological diagnosis was breast cancer (9 [41%] patients). Secukinumab was started after a median of 24 months following cancer diagnosis. At this time point, all but three patients were in oncological remission. No case of cancer relapse or progression was recorded over a median follow-up of 30 months. In the largest cohort reported to date to this regard, secukinumab was not associated with oncological recurrence or progression in patients with spondyloarthritis with a history of malignancy. Secukinumab may, therefore, represent a safe option in this clinical scenario.

Keywords: Cancer; Secukinumab; Spondyloarthritis.

PubMed Disclaimer

References

    1. Bass AR, Abdel-Wahab N, Reid PD, Sparks JA, Calabrese C, Jannat-Khah DP et al (2023) Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis 82(7):920–926 - DOI - PubMed
    1. Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386(4):316–326 - DOI - PubMed
    1. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H (2009) IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway. J Exp Med 206(7):1457 - DOI - PubMed - PMC
    1. Zhao J, Chen X, Herjan T, Li X (2020) Cytokines focus: the role of interleukin-17 in tumor development and progression. J Exp Med 217(1):e20190297 - DOI - PubMed
    1. Chen YS, Huang TH, Liu CL, Chen HS, Lee MH, Chen HW et al (2019) Locally targeting the IL-17/IL-17RA axis reduced tumor growth in a murine B16F10 melanoma model. Hum Gene Ther 30(3):273–285 - DOI - PubMed

Substances

LinkOut - more resources